Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a nerve procedure outlast botox for chronic migraine?

NCT ID NCT07780136

Disease control Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 21, 2026 · Last updated Aug 21, 2026

Summary

This trial compares two interventional treatments for chronic migraine: ultrasound-guided pulsed radiofrequency (PRF) targeting the greater occipital and supratrochlear nerves, versus Botox (onabotulinumtoxinA) injections. The study enrolls adults aged 18-65 with chronic migraine who have not responded to standard preventive medications. The main goal is to see which approach better reduces the number of monthly migraine days, potentially offering a more durable or cost-effective alternative to repeated Botox injections.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ultrasound-guided pulsed radiofrequency (PRF) of the greater occipital and supratrochlear nerves, compared with onabotulinumtoxinA (Botox) injections.
What this could lead to
If PRF proves more effective or longer-lasting than Botox, it could offer a more durable and cost-effective treatment option for chronic migraine sufferers.
What could go wrong
This is a single-center trial with 70 participants, so results may not apply broadly. PRF is a procedure with potential side effects, and its long-term benefits compared to Botox are not yet established.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * • Age between 18 and 65 years, either sex. * Diagnosis of chronic migraine according to the International Classification of Headache Disorders, 3rd edition (ICHD-3) criteria (headache occurring on ≥15 days/month for \>3 months, with migrainous features on ≥8 days/month). * Inadequate response, intolerance, or contraindication to at least one standard oral preventive medication (e.g., amitriptyline, propranolol, topiramate, flunarizine, valproate). * Stable dose of any concurrent prophylactic medication for at least 4 weeks prior to enrolment, with no planned change during the study period. * Willingness and ability to complete headache diaries and follow-up visits. Exclusion Criteria: * • Other primary headache disorders (tension-type headache, cluster headache, hemicrania continua) as the predominant headache type. * Secondary headache due to an identifiable structural, infectious, vascular, or neoplastic cause (confirmed or suspected by history/imaging). * Prior botulinum toxin injection or radiofrequency procedure for headache within the last 6 months. * Known hypersensitivity or allergy to botulinum toxin or to local anesthetics. * Pregnancy or lactation. * Neuromuscular junction disorders (e.g., myasthenia gravis, Lambert-Eaton syndrome). * Medication overuse headache not resolved prior to enrolment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic migraine headache are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

headache disorder migraine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic migraine headache

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.